OncoSec Medical Inc (NASDAQ:ONCS)’s share price shot up 14.1% during trading on Friday . The company traded as high as $2.17 and last traded at $2.11. 4,875,000 shares changed hands during mid-day trading, an increase of 361% from the average session volume of 1,058,083 shares. The stock had previously closed at $1.85.

A number of research firms have recently commented on ONCS. HC Wainwright set a $6.00 price target on OncoSec Medical and gave the stock a “buy” rating in a report on Friday. ValuEngine lowered OncoSec Medical from a “sell” rating to a “strong sell” rating in a research note on Monday, October 2nd. Finally, Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research note on Thursday, October 26th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. OncoSec Medical currently has an average rating of “Buy” and a consensus price target of $5.33.

The firm has a market cap of $72.46, a P/E ratio of -1.98 and a beta of 3.27.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). equities research analysts forecast that OncoSec Medical Inc will post -0.86 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “OncoSec Medical (ONCS) Shares Up 14.1%” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/19/oncosec-medical-oncs-shares-up-14-1.html.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.